Dare Bioscience (NASDAQ:DARE) Stock Passes Below 200-Day Moving Average – What’s Next?

Shares of Dare Bioscience, Inc. (NASDAQ:DARE) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.36 and traded as low as $1.61. Dare Bioscience shares last traded at $1.68, with a volume of 87,831 shares changing hands.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DARE. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Dare Bioscience to a “hold” rating in a report on Saturday, August 16th. Finally, Maxim Group raised shares of Dare Bioscience from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a report on Thursday, September 4th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Dare Bioscience Stock Up 3.1%

The company’s 50 day moving average price is $2.01 and its two-hundred day moving average price is $2.36. The firm has a market cap of $24.01 million, a PE ratio of -0.79 and a beta of 1.14.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. The firm had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.01 million. On average, analysts expect that Dare Bioscience, Inc. will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dare Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of DARE. Raymond James Financial Inc. lifted its stake in shares of Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 13,650 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Dare Bioscience during the third quarter worth $37,000. Finally, AMH Equity Ltd boosted its stake in shares of Dare Bioscience by 17.8% during the second quarter. AMH Equity Ltd now owns 193,603 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 29,301 shares during the period. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.